Supernus Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SUPN and other ETFs, options, and stocks.

About SUPN

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. 

CEO
Jack A. Khattar
CEOJack A. Khattar
Employees
674
Employees674
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2005
Founded2005
Employees
674
Employees674

SUPN Key Statistics

Market cap
2.84B
Market cap2.84B
Price-Earnings ratio
-145.07
Price-Earnings ratio-145.07
Dividend yield
Dividend yield
Average volume
685.23K
Average volume685.23K
High today
$49.53
High today$49.53
Low today
$48.73
Low today$48.73
Open price
$49.25
Open price$49.25
Volume
459.07K
Volume459.07K
52 Week high
$57.65
52 Week high$57.65
52 Week low
$29.16
52 Week low$29.16

Stock Snapshot

Supernus Pharmaceuticals(SUPN) stock is priced at $49.44, giving the company a market capitalization of 2.84B. It carries a P/E multiple of -145.07.

On 2026-01-28, Supernus Pharmaceuticals(SUPN) stock moved within a range of $48.73 to $49.53. With shares now at $49.44, the stock is trading +1.5% above its intraday low and -0.2% below the session's peak.

Trading activity shows a volume of 459.07K, compared to an average daily volume of 685.23K.

Over the past 52 weeks, Supernus Pharmaceuticals(SUPN) stock has traded between a high of $57.65 and a low of $29.16.

Over the past 52 weeks, Supernus Pharmaceuticals(SUPN) stock has traded between a high of $57.65 and a low of $29.16.

SUPN News

Simply Wall St 4d
Recent 3.5% pullback isn't enough to hurt long-term Supernus Pharmaceuticals shareholders, they're still up 64% over 5 years

The simplest way to invest in stocks is to buy exchange traded funds. But in our experience, buying the right stocks can give your wealth a significant boost. F...

Recent 3.5% pullback isn't enough to hurt long-term Supernus Pharmaceuticals shareholders, they're still up 64% over 5 years

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own SUPN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.